Atlas Trials

PTC Therapeutics

64 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch PTC Therapeutics

RecordFirmDate
Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA) (NCT07681713)PTC Therapeutics2026-08-15
A Study of Sepiapterin in Participants With Phenylketonuria (PKU) (NCT06302348)PTC Therapeutics2024-03-04
A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia (NCT05515536)PTC Therapeutics2022-12-08
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia (NCT05485987)PTC Therapeutics2022-10-12
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease (NCT05218655)PTC Therapeutics2022-06-22
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) (NCT05269355)PTC Therapeutics2022-05-23
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS (NCT05349721)PTC Therapeutics2022-05-15
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria (NCT05166161)PTC Therapeutics2022-02-14
A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) (NCT04336826)PTC Therapeutics2021-12-29
A Study of PTC923 in Participants With Phenylketonuria (NCT05099640)PTC Therapeutics2021-09-30
A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants (NCT04903288)PTC Therapeutics2021-05-12
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia (NCT04577352)PTC Therapeutics2020-12-17
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy (NCT04378075)PTC Therapeutics2020-09-28
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) (NCT04439071)PTC Therapeutics2020-07-09
A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I) (NCT03783923)PTC Therapeutics2019-10-31
A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren (NCT03796637)PTC Therapeutics2019-04-11
A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) (NCT03761095)PTC Therapeutics2019-03-13
A Study of CNSA-001 in Women With Diabetic Gastroparesis (NCT03712124)PTC Therapeutics2019-02-27
A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia (NCT03519711)PTC Therapeutics2019-01-03
A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia (NCT04117880)PTC Therapeutics2018-12-31
A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) (NCT03648827)PTC Therapeutics2018-12-21
A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD) (NCT03642145)PTC Therapeutics2018-10-31

Track PTC Therapeutics automatically

Every clearance here is in the API, with alerts when new ones post.